(EZM) WisdomTree U.S. MidCap - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US97717W5702 • Small Value
EZM: Stocks, MidCap, US, Earnings
The WisdomTree U.S. MidCap Earnings Fund (EZM) is an exchange-traded fund (ETF) designed to track the performance of the WisdomTree U.S. MidCap Earnings Index. Under normal market conditions, the fund allocates at least 95% of its total assets to securities that are either components of the index or exhibit economic characteristics closely aligned with those components. This approach ensures the fund stays closely tied to the indexs composition and investment strategy.
The index itself is fundamentally weighted, focusing on mid-capitalization companies within the U.S. stock market that generate earnings. By targeting earnings-generating firms, the fund seeks to provide exposure to companies with established operations and revenue streams. Mid-capitalization companies often represent a sweet spot in the market, offering the growth potential of smaller firms while maintaining the stability associated with larger enterprises. The fund is classified as non-diversified, meaning it can concentrate its holdings in a smaller number of securities, which may increase its potential for higher returns but also raises the risk profile compared to diversified funds.
With total assets under management (AUM) of $798.42 million, the fund is part of the Small Value ETF category. It trades on the NYSE ARCA under the ticker symbol EZM. For more information, investors can visit the funds website at http://www.wisdomtree.com.
Looking ahead, the WisdomTree U.S. MidCap Earnings Fund is well-positioned to capitalize on the evolving dynamics of the U.S. mid-cap market. As earnings growth remains a critical driver of equity valuations, the funds focus on companies with demonstrated profitability could provide a stable foundation in varying market conditions. Additionally, as interest rates continue to shape investor preferences, the funds exposure to mid-cap companies may offer a balance between growth and income potential. Over the long term, the funds fundamentally weighted approach could benefit from a rebalancing effect, as it adjusts to changes in the earnings landscape of its constituents.
Additional Sources for EZM ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EZM ETF Overview
Market Cap in USD | 716m |
Category | Small Value |
TER | 0.38% |
IPO / Inception | 2007-02-23 |
EZM ETF Ratings
Growth Rating | 67.8 |
Fundamental | - |
Dividend Rating | 40.1 |
Rel. Strength | -9.41 |
Analysts | - |
Fair Price Momentum | 53.02 USD |
Fair Price DCF | - |
EZM Dividends
Dividend Yield 12m | 1.30% |
Yield on Cost 5y | 2.70% |
Annual Growth 5y | 0.92% |
Payout Consistency | 92.4% |
EZM Growth Ratios
Growth Correlation 3m | -91.1% |
Growth Correlation 12m | 34.6% |
Growth Correlation 5y | 79.8% |
CAGR 5y | 15.12% |
CAGR/Max DD 5y | 0.64 |
Sharpe Ratio 12m | -0.43 |
Alpha | -9.51 |
Beta | 0.900 |
Volatility | 37.44% |
Current Volume | 16.2k |
Average Volume 20d | 26.1k |
As of April 29, 2025, the stock is trading at USD 57.26 with a total of 16,230 shares traded.
Over the past week, the price has changed by +6.08%, over one month by -3.46%, over three months by -11.32% and over the past year by -0.92%.
Yes. Based on ValueRay Analyses, WisdomTree U.S. MidCap (NYSE ARCA:EZM) is currently (April 2025) a good stock to buy. It has a ValueRay Growth Rating of 67.79 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EZM as of April 2025 is 53.02. This means that EZM is currently overvalued and has a potential downside of -7.4%.
WisdomTree U.S. MidCap has no consensus analysts rating.
According to ValueRays Forecast Model, EZM WisdomTree U.S. MidCap will be worth about 59.5 in April 2026. The stock is currently trading at 57.26. This means that the stock has a potential upside of +3.89%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 59.5 | 3.9% |